McKesson CEO: 'Nonsense' That We Ignored Opioid Crisis

The transcript discusses McKesson's handling of legal challenges related to opioid distribution. It covers the company's responsibilities, operational processes, and efforts to address suspicious orders. McKesson emphasizes its role in fulfilling pharmacy demands while highlighting the complexities of monitoring patient prescriptions. The company reports suspicious orders to the DEA and stresses its commitment to compliance.

In what ways does the speaker claim their company does not interact with patients?

What is the speaker's stance on the relationship between pharmacies and physicians regarding prescriptions?